Navigation Links
Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Date:12/17/2008

estors may participate in the conference call by dialing (877)879-6201 (domestic) or (719)325-4843 (international). To access the live webcast, please visit the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available on the company's website beginning approximately two hours after the call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "expects," "anticipates," "believes," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Forward-looking statements include statements regarding: the timeframe in which Cadence anticipates filing an NDA seeking marketing authorization for Acetavance, and the timeframe in which the company expects to complete its analysis and announce the full results of its clinical trials of Acetavance. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may differ materially from those set forth in
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... Lowcostcarinsuranceprice.com has released a new blog post ... auto insurance prices . , Drivers who live ... may have to pay more for auto insurance plans ... can also offer protection against vehicle theft. , ... on a single website: http://lowcostcarinsuranceprice.com/ . Drivers ...
(Date:4/18/2015)... the past few weeks, TheBeautyPlace.com has been undergoing maintenance ... run maintenance on our shipping facilities to update software ... Director. "It disrupted our regular shipping schedule but we ... track after having completed the maintenance." , Now, TheBeautyPlace.com ... has not allowed some calls to come in through ...
(Date:4/18/2015)... “ ArcAngel ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, ... technology expert, conducted the app review and shared with viewers ... a turbulent world, people may find themselves in dangerous situations ... first move, but some situations can be avoided if there ...
(Date:4/17/2015)... John Evans, a Gardant affordable assisted living community, ... p.m. to 3 p.m. on April 24. , The ... Pekin, Illinois, serves older adults of all incomes, including ... their independence. , Becky Baker will entertain guests on ... during the luau. , For more information, call 309-477-8800. ...
(Date:4/17/2015)... Alcohol and Violence , The National Council on ... driving has been the focus of much public and ... between alcohol and crime received less public attention. , ... assault, and their relationship to alcohol have been clearly ... in America were drinking alcohol at the time of ...
Breaking Medicine News(10 mins):Health News:High Rates Of Car Theft Can Have An Impact on Auto Insurance Prices! 2Health News:TheBeautyPlace.com Temporary Number Available 2Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3
... winners and finalists of the 2010 Prix Galien USA and ... issue of Annals of the New York Academy of ... in biopharmaceutical research, recognizes outstanding achievements in improving the global ... Established in 1970, Prix Galien is the most ...
... live broadcast from the University of Southampton today (4 ... preventing the spread of antibiotic-resistant organisms, such as MRSA, ... this week,s World Health Day ,Antimicrobial resistance and ... laboratory at the University of Southampton used state-of-the-art fluorescent ...
... scientists know this about glioblastoma multiforme: the malignant brain ... in different permutations. In a novel effort ... of University of Cincinnati (UC) researchers has begun sequencing ... They hope that by mapping the various DNA rearrangements ...
... - Adolescents represent the majority of people who binge drink. ... surveys indicate that episodes of heavy alcohol drinking within the ... graders, 22 percent of 10th graders, 28 percent of 12th ... adolescence, roughly between 12 to 20 years of age, marks ...
... Attention Deficit Hyperactivity Disorder, or ADHD, is widely recognized by ... in place. But as many as six percent of all ... Demonstrating a lack of refined motor skills, children with DCD ... staying organized at school. They appear to be uncoordinated ...
... edition of The Royal Marsden Hospital Manual of Clinical ... new format that organises 15 key chapters into four ... content on areas such as risk management and preparing ... nurses from the world-renowned UK centre of excellence, the ...
Cached Medicine News:Health News:Prix Galien winners published in Annals of the New York Academy of Sciences 2Health News:MRSA eliminated by copper in live global broadcast 2Health News:University of Cincinnati team to track tumor DNA through bloodstream 2Health News:University of Cincinnati team to track tumor DNA through bloodstream 3Health News:Underage binge drinking can create lasting brain changes 2Health News:Clumsy kids who don't 'grow out of it' 2Health News:Patient's journey format drives new edition of vital student nurse manual 2Health News:Patient's journey format drives new edition of vital student nurse manual 3
(Date:4/17/2015)... , April 17, 2015 ... leading Life Science and High Technology company, today ... Pacific headquarters and state-of-the-art Cell Culture ... Park, the facility will provide customized support to ... scientific capabilities. "Our new Technical Center ...
(Date:4/16/2015)... Mindray Medical International Limited (NYSE: MR ... medical devices worldwide, announced today that it has ... Report on Form 20-F that included audited financial ... electronic version of Mindray,s Annual Report on Form ... at  http://ir.mindray.com  or  http://www.sec.gov . Investors ...
(Date:4/16/2015)... THOUSAND OAKS, Calif. , April 16, 2015 /PRNewswire/ ... will report its first quarter financial results on Tuesday, ... financial markets. The announcement will be followed by a ... PT. Participating in the call from Amgen will be ... officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 2Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 3Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 4Sigma-Aldrich Expands Customer-Centric Model with Investments in Singapore That Localize World-Class Capabilities to Better Support Customers in Asia 5Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2
... Showed Sustained Improvements in Blood Glucose,Control and ... 2007 /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. and Eli ... study that showed BYETTA(R) (exenatide) injection,sustained improvements ... through three and a half years of ...
... WIRE)--Jun 25, 2007 - HepaLife Technologies, Inc.,(OTCBB: ... that new,data presented at an international influenza ... line outperforms,current cell technologies at replicating human ... step towards the production of,a cell-culture based ...
Cached Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 2HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 3HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 4HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 5HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove,Superior at International Conference 6
... Plus Long Instrument for applications ... VERSASTEP™ Plus Long Instrument with ... unique endoscopic entry device that ... It is used to establish ...
... components are supplied sterile. , ,The Step™ ... sterile in 2/3, 5, 7/8, 10 and 12 ... They are used in conjunction with the Step™ ... Expandable Sleeve. The 5, 7/8, 10 and 12 ...
BLUNTPORT Plus Single Use Converterless 5 mm - 12 mm Trocar System for Open Laparoscopy....
... VERSAPORT™ RT cannulas are all able to ... packaged for use with the RT system. ... all able to be used with the ... the RT system. The trocars include: VERSAPORT™ ...
Medicine Products: